Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 10.14%.

  • Kiniksa Pharmaceuticals International's EBITDA Margin rose 213700.0% to 10.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.99%, marking a year-over-year increase of 83600.0%. This contributed to the annual value of 10.25% for FY2024, which is 154400.0% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its EBITDA Margin stood at 10.14% for Q3 2025, which was up 213700.0% from 11.44% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBITDA Margin peaked at 226.07% during Q3 2022, and registered a low of 538.88% during Q2 2021.
  • Its 5-year average for EBITDA Margin is 51.5%, with a median of 9.29% in 2024.
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBITDA Margin skyrocketed by 4792000bps in 2022 and then tumbled by -2467500bps in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBITDA Margin (Quarter) stood at 193.94% in 2021, then soared by 98bps to 3.09% in 2022, then surged by 1081bps to 30.27% in 2023, then plummeted by -124bps to 7.35% in 2024, then skyrocketed by 238bps to 10.14% in 2025.
  • Its EBITDA Margin stands at 10.14% for Q3 2025, versus 11.44% for Q2 2025 and 6.2% for Q1 2025.